Study to test if patient education improves side effect management for neuroendocrine tumor patients on oral therapy
NCT ID NCT07258810
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will enroll 100 adults with neuroendocrine tumors who are starting oral anti-cancer drugs like everolimus or sunitinib. Researchers want to see if a therapeutic education program—including questionnaires and nurse consultations—helps patients handle side effects and maintain quality of life. The main focus is on tracking severe side effects (grade 3-5) over three months and comparing outcomes between those who get the education program and those who do not.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- therapeutic education program (questionnaires and consultations)
- What this could lead to
- If successful, this could show that patient education programs help people with neuroendocrine tumors handle side effects better and stick to their oral cancer treatment.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test a new drug or cure, and results may not apply to all patients or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE (NE) TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Edouard Herriot University Hospital
Lyon, 69003, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pharmacists get training to better support cancer patients on oral medications
- Can better education reduce PICC line risks?
- New hope for rare gut tumors? phase 2 trial launches
- New PET scan could slash radiation by 100x
- New study aims to reduce harmful side effects in rare cancer patients
- Europe-Wide study to settle debate on surgery for spread gut tumors